KOSDAQBiotech & Pharma084650

LabGenomics

₩1,861▲ 1.47%2026-11-18 close
Market Cap
₩27.6B
Turnover
₩59,847,178
Volume
30K
Shares out.
14.9M
PER
—
PBR
0.2×
EPS
-₩3,592
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Loss narrowing at a molecular diagnostics firm; restructuring payoff is the test

LabGenomics finished restructuring its domestic and US operations in 2026 and has narrowed quarterly operating losses, yet revenue has fallen for four straight quarters and the net loss attributable to controlling shareholders over the last four quarters totals KRW 53.3 billion, so whether second-half margin gains appear in reported figures is the central question.

  1. 1

    Operating loss reached KRW 53.5 billion in 2025, the third straight year of losses, and the operating margin fell from 45.7% in 2022 to -60.7% in 2025.

  2. 2

    Third-quarter 2026 revenue was KRW 13.7 billion, extending a four-quarter decline and down 40.7% from a year earlier.

  3. 3

    On September 23, 2026 the company said it had completed the consolidation of its US laboratories and the reshaping of its domestic outsourcing structure, and reported a first-half 2026 consolidated operating loss of KRW 11 billion, about 57% smaller than a year earlier.

  4. 4

    The US subsidiary signed an exclusive US license for cancer diagnostics with liquid biopsy company Dxome on August 7, 2026, securing three precision molecular panels covering blood cancers, minimal residual disease and lymphoma ctDNA.

  5. 5

    Trading resumed on September 23, 2026 after a 5-for-1 share consolidation, and on October 29, 2026 the stock was designated a one-day investment caution issue because of concentrated trading in a small number of accounts.

02

Business structure

LabGenomics is a healthcare company specializing in molecular diagnostics, centered on genetic analysis-based testing services.

According to JobKorea company information as of March 2026, revenue is split into molecular diagnostics and genetic testing services at 76%, general diagnostic specimen analysis services at 14%, research services at 9%, and diagnostic products at 1%.

Overseas, the business centers on US clinical laboratories (CLIA Labs).

In the company's investor letter dated June 29, 2026, QDx, acquired at the end of 2023, is described as accounting for roughly half of consolidated revenue, and the company said it turned profitable on a standalone basis in 2025, two years after the acquisition.

The same letter says IMD remains loss-making as a result of efficiency work across the CLIA Labs. In a September 2026 announcement, the company said it merged the overlapping testing functions and operating teams of QDx and IMD in the US and unified them under the single brand 'LabGenomics'.

Domestically, the company is reshaping its outsourcing structure toward profitability as the specimen outsourcing system changes.

In higher-value areas, its US unit signed a license with Dxome, a liquid biopsy company, to secure three precision molecular panels covering blood cancers, minimal residual disease and lymphoma ctDNA. JobKorea's company profile lists growth through a domestic hospital network as a company strategy.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩23B-₩2.1B−9.2%
2025Q4₩20.9B-₩25.5B−122.0%
2026Q1₩17.9B-₩4.2B−23.3%
2026Q2₩15.8B-₩6.9B−43.6%
2026Q3₩13.7B-₩3.5B−25.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩144.8B₩66.2B₩48.4B45.7%23.1%19.1%
2023₩73.1B-₩6.8B-₩4.7B−9.3%−2.1%37.4%
2024₩85.9B-₩18.5B-₩23.8B−21.5%−11.0%36.7%
2025₩88.2B-₩53.5B-₩64.4B−60.7%−43.0%53.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue went from KRW 144.8 billion in 2022 to KRW 73.1 billion in 2023, a 49.5% decline, before rising to KRW 85.9 billion in 2024 (up 17.5%) and KRW 88.2 billion in 2025 (up 2.6%), two straight years of growth after the 2023 low.

Operating profit of KRW 66.2 billion in 2022 turned into an operating loss of KRW 6.79 billion in 2023, and the losses widened to KRW 18.5 billion in 2024 and KRW 53.5 billion in 2025.

The operating margin fell from 45.7% in 2022 to -9.3% in 2023, -21.5% in 2024 and -60.7% in 2025, making 2023 through 2025 three straight years of losses.

The net loss attributable to controlling shareholders was KRW 4.67 billion in 2023, KRW 23.8 billion in 2024 and KRW 64.4 billion in 2025, while the total net loss including non-controlling interests was also KRW 64.4 billion in 2025.

The company attributes much of the 2025 loss to one-off accounting charges, including large bad-debt provisions on head-office receivables, and said in its June 2026 investor letter that excluding them, consolidated operating profit improved 12% year on year.

Operating cash flow moved from KRW 69 billion in 2022 to -KRW 3.83 billion in 2023, -KRW 13 billion in 2024 and -KRW 30.5 billion in 2025. The debt ratio rose from 19.1% in 2022 to 53.8% in 2025, with year-end 2025 total equity of KRW 149.6 billion and total liabilities of KRW 80.5 billion.

Quarterly revenue slid from KRW 23 billion in Q3 2025 to KRW 20.9 billion in Q4 2025 (down 9.2% QoQ), KRW 17.9 billion in Q1 2026 (down 14.3%), KRW 15.8 billion in Q2 2026 (down 12.1%) and KRW 13.7 billion in Q3 2026 (down 13.3% QoQ and 40.7% YoY), a four-quarter decline.

Operating losses went from KRW 2.12 billion in Q3 2025 to KRW 25.5 billion in Q4 2025, then narrowed to KRW 4.18 billion in Q1 2026, widened to KRW 6.87 billion in Q2 2026 and narrowed again to KRW 3.46 billion in Q3 2026, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 53.3 billion.

The company also said on September 23, 2026 that its first-half 2026 consolidated operating loss was KRW 11 billion, about 57% smaller than a year earlier.

05

Industry analysis

The company's own assessment is that China-style volume growth is becoming hard in the domestic molecular diagnostics market, as specimen outsourcing rules change and competition intensifies.

In response, the company removed non-core test items in 2026 and reshaped its portfolio around profitability and technological competitiveness. According to the company's announcement, first-half 2026 standalone revenue fell 51% year on year, while standalone operating loss narrowed by 83% over the same period.

In the US, the CLIA laboratory business is the core, and the company reported that second-quarter 2026 CLIA Lab revenue of KRW 13.2 billion rose 11% from the prior quarter. The company expects cost ratios and operating cash flow to improve gradually as expanded laboratory-developed testing (LDT) work continues.

In the US, the company is responding by combining QDx and IMD into a single laboratory structure to raise scale efficiency. In August 2026 the company also announced plans to pursue a US blood cancer market it sizes at about 190,000 patients a year.

The three precision panels are presented by the company as part of an expansion of its higher-value testing portfolio.

06

Outlook

In its September 23, 2026 announcement the company said it is pursuing revenue growth and margin improvement in the second half of 2026.

In its June 2026 investor letter, the company expects the sales-staff expansion and cost reductions at US unit QDx to produce visible gains in revenue and profitability from the second half of 2026.

The company expects IMD to improve gradually after the second half of 2026, as its focus on higher-value NGS-based work and efficiency measures take effect.

Having secured blood cancer and minimal residual disease panels through its August 2026 Dxome license, the company says it is moving into the US blood cancer market in earnest.

First-half 2026 consolidated operating loss narrowed and second-quarter US CLIA Lab revenue rose, but whether these gains carry into second-half results is the challenge the company itself has identified.

The company reported that first-quarter 2026 consolidated operating profit improved 26% year on year and standalone operating profit turned positive, and it says it will keep pursuing efficiency.

Domestically, the restructuring of the outsourcing structure in response to specimen outsourcing rule changes was in its final stage as of September 2026. The next periodic report, the 2026 annual report, will show whether the revenue decline has reversed and whether the operating margin has improved.

07

Valuation

PER
—
PBR
0.2×
ROE
-33.1%
EPS
-₩3,592
BPS
₩8,968
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the company has posted net losses over the last four quarters. The price-to-book ratio sits well below 1x, meaning the share price is low relative to book equity on the balance sheet.

Losses have accumulated, however, so the PBR level shows where the price stands against assets but does not indicate when earnings will recover. The dividend yield is effectively near zero, so comparisons based on dividends do not apply.

The 5-for-1 share consolidation in August 2026 changed the per-share price basis, so direct comparison with pre-consolidation prices is not meaningful.

Setting the KRW 53.3 billion net loss attributable to controlling shareholders over the last four quarters against year-end 2025 total equity of KRW 149.6 billion gives a sense of how fast equity is being used up.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Narrowing losses

The company said in its June 2026 letter that first-quarter 2026 consolidated operating profit improved 26% year on year. Its September announcement put the first-half 2026 consolidated operating loss at KRW 11 billion, about 57% smaller than a year earlier.

The third-quarter 2026 operating loss of KRW 3.46 billion was below the second-quarter figure of KRW 6.87 billion.

US laboratory revenue rebound

The company reported that second-quarter 2026 revenue from its US CLIA Lab business rose 11% from the prior quarter to KRW 13.2 billion, while the operating loss narrowed 27%.

The company points to QDx's record of turning profitable on a standalone basis and to the expected effect of a larger sales team in the second half of 2026. Whether QDx, which accounts for about half of consolidated revenue, keeps growing in the second half is the key check for the bullish case.

Expanding precision diagnostics portfolio

Through its license with Dxome, the US unit secured three panels covering blood cancers, minimal residual disease and lymphoma ctDNA. In August 2026 the company said it was moving in earnest into a US blood cancer market of about 190,000 patients a year. Consolidated cash and cash equivalents stood at KRW 61.9 billion at the end of the first half of 2026.

09

Bear factors

Persistent operating losses and cash outflow

The 2025 operating loss of KRW 53.5 billion marked a third straight year of losses, with an operating margin of -60.7%. Operating cash flow was also negative at -KRW 30.5 billion in 2025, continuing a pattern that began in 2023.

The net loss attributable to controlling shareholders over the last four quarters totals KRW 53.3 billion, so the narrower quarterly losses have not yet reached the annual totals.

Continued revenue decline

Third-quarter 2026 revenue of KRW 13.7 billion marked a fourth consecutive quarterly decline and was down 40.7% from a year earlier. Standalone revenue for the first half of 2026 fell 51% year on year, according to the company's announcement.

The company's own view that domestic growth is difficult under the changed specimen outsourcing system is consistent with this trend.

Market surveillance and listing-standard issues

On August 5, 2026 the exchange published a market notice flagging the stock as a possible administrative-issue candidate. On October 29, 2026 it was designated for one day as an investment caution issue due to concentrated trading in a few accounts.

The exchange disclosure showed the stock had risen 18.53% over three days, with the top ten accounts accounting for over 40% of buying.

10

Risk factors

Financial and liquidity

At the end of the first half of 2026, consolidated borrowings were KRW 69.2 billion against cash and cash equivalents of KRW 61.9 billion. The debt ratio rose to 53.8% at year-end 2025 from 19.1% in 2022. As long as operating cash flow stays negative, repayment capacity depends on the company's financing plans.

Trading and market surveillance

The one-day investment caution designation and the administrative-issue warning show that sharp price moves drew exchange scrutiny. The 5-for-1 share consolidation changed both the number of shares and the per-share price basis. Exchange market notices on listing requirements are confirmed through disclosures.

Business and regulatory

The company itself says domestic growth is difficult because the specimen outsourcing system is changing. If IMD's losses do not improve after the second half of 2026, the recovery in consolidated profit will be delayed.

The pace at which the Dxome panels are commercialized and begin to contribute revenue is another variable to track.

11

What to watch next

  1. Late March 2027

    This is the filing date for the 2026 annual report, which will show whether annual revenue broke the four-quarter decline and whether the operating margin improved from -60.7% in 2025.

  2. Around May 15, 2027

    This is the filing deadline for the first-quarter 2027 report, where the key checks are whether revenue keeps falling and whether the operating loss is smaller than the KRW 4.18 billion posted in Q1 2026.

  3. End of December 2026

    This marks the end of the 2026 fiscal year, when the revenue contribution from the US blood cancer panels and the status of exchange market notices are settled on a year-end basis.

12

Overall view

LabGenomics has posted operating losses for three straight years since turning from profit to loss in 2023, and in 2026 it finished restructuring its business and narrowed quarterly operating losses.

On the positive side, first-half 2026 consolidated operating loss fell about 57% year on year, second-quarter US CLIA Lab revenue rose 11% from the prior quarter, and the Dxome license secured blood cancer and minimal residual disease panels.

On the negative side, third-quarter 2026 revenue fell for a fourth straight quarter and was down 40.7% from a year earlier, the net loss attributable to controlling shareholders over the last four quarters totals KRW 53.3 billion, and operating cash flow was -KRW 30.5 billion in 2025.

The company says consolidated operating profit improved 12% excluding one-off charges in 2025, but that basis differs from reported figures. Year-end 2025 total equity was KRW 149.6 billion and the debt ratio rose to 53.8%.

The company has no meaningful price-to-earnings ratio because of losses, and its price-to-book ratio sits well below 1x, so how asset value and the pace of earnings recovery line up is the core question. This text does not contain an investment rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. labgenomics.co.kr
  2. jobkorea.co.kr
  3. comp.wisereport.co.kr
  4. orgo.kr
  5. labgenomics.co.kr
  6. all.allroundnote.com
  7. topstarnews.net
  8. newspim.com
  9. m.irgo.co.kr
  10. comp.fnguide.com
  11. comp.wisereport.co.kr
  12. investing.com
  13. edaily.co.kr
  14. sec.gov
  15. etoday.co.kr
  16. judal.co.kr
  17. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis